SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3051Isis Pharmaceuticals Initiates Phase III Study of ISIS 3521 In Non-Small Cell LuSemiBull-10/18/2000
3050bob, Not to be a wet blanket, but Roche has a history of messing with its partntuck-10/10/2000
3049RadioWallStreet.com: Roth Capital Partners and the New Economy PHILADELPHIAbob zagorin-10/10/2000
3048Isis Pharmaceuticals Announces Licensing of Chemistry Patents To Roche Molecularbob zagorin-10/10/2000
3047Isis Pharmaceuticals Announces Licensing of Chemistry Patents To Roche MolecularSemiBull-10/10/2000
3046SemiBull, And another plug for Isis, amazingly, not McCamant! tfc.com Cheers,tuck-10/5/2000
3045What Are the Hot Biotech Stocks? (James McCamant mentions ISIP) biz.yahoo.comSemiBull-10/5/2000
3044Reminds me of an old saying: If you torture the data long enough, they'll adThe Band Leader-10/4/2000
3043Thread, Does anyone think I-2302 might benefit from an enhanced delivery systemtuck-10/4/2000
3042Isis Pharmaceuticals to Reinitiate Development of ISIS 2302 in Crohn's Diseabob zagorin-10/4/2000
3041Isis Pharmaceuticals to Reinitiate Development of ISIS 2302 in Crohn's DiseaSemiBull-10/4/2000
3040Can someone please help me understand the sale of patents to Coley? Looks to meThe Band Leader-9/29/2000
3039Thursday September 28, 8:07 am Eastern Time Press Release SOURCE: Coley Pharmacebob zagorin-9/28/2000
3038Coley Pharmaceutical Group Strengthens Leadership in Immune Stimulation With AcqSemiBull-9/28/2000
3037100 Biotech Investors Cram into L'Auberge; IR PR Strategies, LLC Announces Nbob zagorin-9/28/2000
3036Yeah, good point regarding the bottom line. Typical of ISIP- the next MSFT. ThThe Band Leader-9/25/2000
3035This sounds good, but what does it do to the bottom line? Isis Pharmaceuticals&juneau_boy-9/25/2000
3034Isis Pharmaceuticals Broadens Licensing of Third-Generation Antisense Chemistry bob zagorin-9/20/2000
3033cheers back at ya. i've been out of townbob zagorin-9/11/2000
3032bob, Beat ya! Message 14328593 Cheers, Tucktuck-9/5/2000
3031DALLAS--(BUSINESS WIRE)--Aug. 25, 2000--The following conference calls and interbob zagorin-8/25/2000
3030Jubak's Biotech Picks Contains information pertaining to Symbol: ISIS Pharmabob zagorin-8/15/2000
3029reiterated buy this a.m. ISIS Pharm ISIP Roth Capital Buy $20bob zagorin-8/10/2000
3028Looks as if ISIS has 2 years cash on hand a Type 11 Diabetes drug coming into dejuneau_boy-8/10/2000
3027More publicity on ISIS NSCLC trial-nothing new, but continuing exposure-- biospjuneau_boy-8/7/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News